Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer

Phase 1

Completed

• Conditions: Ovarian Carcinoma
• Interventions: Drug: SPARC147609; Drug: Reference147609

• Registration Number: NCT00862355
• Lead Sponsor: Sun Pharma Advanced Research Company Limited

Brief Summary

Bioequivalence study of SPARC147609

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-03-13
• Study First Submitted QC: 2009-03-13
• Study First Posted: 2009-03-16
• Study Start: 2010-03
• Primary Completion: 2010-12
• Study Completion: 2011-01
• Status Verified: 2019-05
• Last Update Submitted: 2019-05-02
• Last Update Posted: 2019-05-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

• Subjects meeting all of the following criteria will be considered for enrollment in the study:

  • Availability of subject for the entire study period and willingness to adhere to protocol requirements.
  • Patients with documented diagnosis of Ovarian Cancer and eligible for receiving a dose 50mg/m2 of Doxorubicin liposome(preferably on no other concomitant medication, however, if considered necessary, to be documented and given).
  • Patients at least 18-years of age or older. iv. Subjects who have no evidence of underlying disease (except ovarian cancer) during screening medical history and whose physical examination is performed within 21 days prior to commencement of the study.
  • Patients with Performance ≤ 2 on the ECOG performance scale. vi. Subjects whose screening laboratory values are within normal limits or considered by the clinical Investigator/Co-Investigator to be of no clinical significance.
  • Informed consent form given in written form.

Exclusion Criteria

• History or presence of significant:

  • Allergy or Significant history of hypersensitivity or idiosyncratic reactions to Doxorubicin Hydrochloride and/or any related compounds etc.
  • Cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
  • Alcohol dependence, alcohol abuse or drug abuse or addiction with any recreational drug within past one year.
  • Clinically significant illness (except ovarian cancer)within 4 weeks before the start of the study v. Positive result to HIV, HCV, RPR and HBsAg.
  • Use of enzyme-modifying drugs (like Phenytoin, Carbamazepine, Barbiturates, Gresiofulvine etc.) in the previous 30 days before day 1 of this study and during the study.

• Donation of 350 mL or more of blood in the previous 90 days before day 1 of this study.

• Participation in another clinical trial within the preceding 90 days of study start

• Subjects who have:

  • Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg
  • Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg
  • Pulse rate below 60/min. or above 100/min

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	SPARC147609	SPARC147609
2	Reference147609	Reference147609

Primary Outcome Measures

Name	Time	Method
90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference product	2 cycles

Secondary Outcome Measures

Name	Time	Method
Treatment emergent adverse events	2 cycles

Trial Locations

Locations (1)

SPARC Site 1; 🇮🇳 Hyderabaad, Andhra Pradesh, India